Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
Klement P, Fiedler W, Gabdoulline R, Dallmann LK, Wienecke CP, Schiller J, Kandziora C, Teich K, Heida B, Büttner K, Brandes M, Funke C, Wichmann M, Othman B, Chromik J, Amberg S, Kebenko M, Schlipfenbacher V, Wilke AC, Modemann F, Janning M, Serve H, Bokemeyer C, Theile S, Deppermann U, Kranich AL, Ganser A, Thol F, Heuser M. Klement P, et al. Among authors: kebenko m. Ann Hematol. 2023 Feb;102(2):323-328. doi: 10.1007/s00277-022-05075-4. Epub 2022 Dec 28. Ann Hematol. 2023. PMID: 36576532 Free PMC article.
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk RF. Fiedler W, et al. Among authors: kebenko m. Br J Haematol. 2015 Jun;169(5):694-700. doi: 10.1111/bjh.13353. Epub 2015 Mar 29. Br J Haematol. 2015. PMID: 25818407 Free article. Clinical Trial.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
Kebenko M, Goebeler ME, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, Friedrich M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W. Kebenko M, et al. Oncoimmunology. 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710. eCollection 2018. Oncoimmunology. 2018. PMID: 30221040 Free PMC article.
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Krauter J, Fiedler W, Schlenk RF, Paschka P, Thol F, Lübbert M, Wattad M, Verbeek M, Könecke C, Neuhaus B, Papkalla A, Kebenko M, Janning M, Döhner K, Gaidzik VI, Becker H, Greil C, Reimer P, Götze KS, Döhner H, Ganser A, Heuser M. Krauter J, et al. Among authors: kebenko m. Br J Haematol. 2018 Oct;183(2):235-241. doi: 10.1111/bjh.15546. Br J Haematol. 2018. PMID: 30378121 Free article. Clinical Trial.
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V, Christine Wilke A, Modemann F, Janning M, Serve H, Ganser A, Bokemeyer C, Theile S, Deppermann U, Kranich AL, Heuser M. Fiedler W, et al. Among authors: kebenko m. Br J Haematol. 2020 Aug;190(3):e169-e173. doi: 10.1111/bjh.16804. Epub 2020 Jun 9. Br J Haematol. 2020. PMID: 32515072 Free article. Clinical Trial. No abstract available.
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.
Ochsenreither S, Fiedler WM, Conte GD, Macchini M, Matos I, Habel B, Ahrens-Fath I, Raspagliesi F, Lorusso D, Keilholz U, Rolling C, Kebenko M, Klinghammer KF, Saavedra O, Baumeister H, Zurlo A, Garralda E. Ochsenreither S, et al. Among authors: kebenko m. ESMO Open. 2022 Apr;7(2):100447. doi: 10.1016/j.esmoop.2022.100447. Epub 2022 Apr 6. ESMO Open. 2022. PMID: 35397434 Free PMC article. Clinical Trial.
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].
Ochsenreither S, Fiedler WM, Del Conte G, Macchini M, Matos I, Habel B, Ahrens-Fath I, Raspagliesi F, Lorusso D, Keilholz U, Rolling C, Kebenko M, Klinghammer KF, Saavedra O, Baumeister H, Zurlo A, Garralda A. Ochsenreither S, et al. Among authors: kebenko m. ESMO Open. 2022 Aug;7(4):100549. doi: 10.1016/j.esmoop.2022.100549. Epub 2022 Jul 13. ESMO Open. 2022. PMID: 35841804 Free PMC article. No abstract available.
15 results